Advertisement
Journal Home
Search for

Volume 80, Issue 1, Pages 7-17 (July 2009)


View previous. 5 of 19 View next.

Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density

Andrew M. KaunitzaCorresponding Author Informationemail address, Philip D. Darneyb, Douglas Rossc, Kevin D. Wolterd, Leon Speroffe

Received 28 July 2008; received in revised form 5 February 2009; accepted 5 February 2009. published online 31 March 2009.

Abstract 

Background

A formulation of depot medroxyprogesterone acetate (DMPA) has been developed that allows subcutaneous injection (104 mg/0.65 mL; DMPA-SC) and achieves highly effective contraception with a similar tolerability profile to intramuscular DMPA (150 mg/mL; DMPA-IM).

Study Design

This randomized, evaluator-blinded study was designed to compare efficacy, safety, and user satisfaction in women receiving DMPA-SC (n=266) or DMPA-IM (n=268) for 2 years with an option to continue for a third year. The primary objectives were to evaluate bone mineral density (BMD) changes and contraceptive efficacy after 2 years.

Results

A total of 225 women completed the first 2 years of this study (DMPA-SC, n=116; DMPA-IM, n=109). After 2 years of DMPA use, BMD loss was marginally smaller in the DMPA-SC group than in the DMPA-IM group at both the total hip (−3.3% and −3.6%, respectively) and lumbar spine (−4.3% and −5.0%, respectively). In those women who received DMPA during the third year, there were no statistically significant differences in BMD loss between DMPA-SC and DMPA-IM groups at the end of Year 3. Recovery of BMD was observed in the small subpopulation of women who had discontinued DMPA-SC or DMPA-IM after the second year. The 2-year treatment-failure cumulative pregnancy rate was 0% in the DMPA-SC group and 0.8% (95% confidence interval, 0.00–2.37%) in the DMPA-IM group (life-table method). Adverse events were similar in the two groups except that injection site reactions were more common in the DMPA-SC group.

Conclusion

DMPA-SC is an effective and well-tolerated contraceptive option, providing comparable efficacy and BMD safety to DMPA-IM.

a Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL 32209, USA

b Department of Obstetrics, Gynecology, and Reproductive Sciences, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA

c Pfizer Inc., New York, NY 10017, USA

d Pfizer Global Research and Development, New London, CT 06320, USA

e Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA

Corresponding Author InformationCorresponding author. Tel.: +1 904 244 3109; fax: +1 904 244 3658.

PII: S0010-7824(09)00045-6

doi:10.1016/j.contraception.2009.02.005


View previous. 5 of 19 View next.

Advertisement